Status:
COMPLETED
DARWIN Study: A Randomization/Withdrawal Efficacy Study of Dexloxiglumide in Constipation-Predominant Irritable Bowel Syndrome (C-IBS)
Lead Sponsor:
Rottapharm
Conditions:
Irritable Bowel Syndrome
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
Irritable Bowel Syndrome (IBS) is the most commonly identified functional gastrointestinal disorder, affecting 10-20% of the population in the Western world, seen predominantly in females and with a n...
Eligibility Criteria
Inclusion
- Rome II criteria for IBS and manifesting supportive symptoms for the sub-classification of C-IBS, with a disease of at least moderate severity.
Exclusion
- standard exclusions apply
Key Trial Info
Start Date :
July 1 2003
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00220090
Start Date
July 1 2003
Last Update
May 14 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Academic Department of Medicine Wythenshawe Hospital
Manchester, United Kingdom